Literature DB >> 25092772

Successful Treatment of a Progressive BRAF V600E-Mutated Anaplastic Pleomorphic Xanthoastrocytoma With Vemurafenib Monotherapy.

Eudocia Q Lee1, Sandra Ruland2, Nicole R LeBoeuf3, Patrick Y Wen4, Sandro Santagata5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25092772     DOI： 10.1200/JCO.2013.51.1766

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  33 in total

1.  Uncommon low-grade brain tumors.

Authors:  Thankamma Ajithkumar; Naduni Imbulgoda; Elliott Rees; Fiona Harris; Gail Horan; Amos Burke; Sarah Jefferies; Stephen Price; Justin Cross; Kieren Allinson
Journal:  Neuro Oncol       Date:  2019-02-14       Impact factor: 12.300

2.  Pleomorphic Xanthoastrocytoma: Natural History and Long-Term Follow-Up.

Authors:  Cristiane M Ida; Fausto J Rodriguez; Peter C Burger; Alissa A Caron; Sarah M Jenkins; Grant M Spears; Dawn L Aranguren; Daniel H Lachance; Caterina Giannini
Journal:  Brain Pathol       Date:  2014-12-05       Impact factor: 6.508

3.  Impact of WHO 2016 update of brain tumor classification, molecular markers and clinical outcomes in pleomorphic xanthoastrocytoma.

Authors:  Raees Tonse; Tejpal Gupta; Sridhar Epari; Jayant Goda Shastri; Mamta Gurav; Nazia Bano; Rakesh Jalali
Journal:  J Neurooncol       Date:  2017-11-16       Impact factor: 4.130

4.  BRAF VE1 immunoreactivity patterns in epithelioid glioblastomas positive for BRAF V600E mutation.

Authors:  Bette K Kleinschmidt-DeMasters; Dara L Aisner; Nicholas K Foreman
Journal:  Am J Surg Pathol       Date:  2015-04       Impact factor: 6.394

Review 5.  New Molecular Considerations for Glioma: IDH, ATRX, BRAF, TERT, H3 K27M.

Authors:  Michael Karsy; Jian Guan; Adam L Cohen; Randy L Jensen; Howard Colman
Journal:  Curr Neurol Neurosci Rep       Date:  2017-02       Impact factor: 5.081

6.  Successful treatment of a BRAF V600E-mutant extracranial metastatic anaplastic oligoastrocytoma with vemurafenib and everolimus.

Authors:  Liangliang Shi; Zhenwei Zou; Qian Ding; Qing Liu; Hongxia Zhou; Xiaohua Hong; Gang Peng
Journal:  Cancer Biol Ther       Date:  2018-11-21       Impact factor: 4.742

7.  Primary Meningeal Pleomorphic Xanthoastrocytoma With Anaplastic Features: A Report of 2 Cases, One With BRAF(V600E) Mutation and Clinical Response to the BRAF Inhibitor Dabrafenib.

Authors:  Aisulu Usubalieva; Christopher R Pierson; Christina A Kavran; Kristin Huntoon; Oleksandr N Kryvenko; Theodore G Mayer; Weiqiang Zhao; Jack Rock; Mario Ammirati; Vinay K Puduvalli; Norman L Lehman
Journal:  J Neuropathol Exp Neurol       Date:  2015-10       Impact factor: 3.685

8.  Marked functional recovery and imaging response of refractory optic pathway glioma to BRAFV600E inhibitor therapy: a report of two cases.

Authors:  Santhosh A Upadhyaya; Giles W Robinson; Julie H Harreld; Paul D Klimo; Mary Ellen Hoehn; Brent A Orr; Ibrahim A Qaddoumi
Journal:  Childs Nerv Syst       Date:  2018-02-01       Impact factor: 1.475

Review 9.  The Role of Molecular Diagnostics in the Management of Patients with Gliomas.

Authors:  Hans-Georg Wirsching; Michael Weller
Journal:  Curr Treat Options Oncol       Date:  2016-10

Review 10.  Glioma Subclassifications and Their Clinical Significance.

Authors:  Ricky Chen; Matthew Smith-Cohn; Adam L Cohen; Howard Colman
Journal:  Neurotherapeutics       Date:  2017-04       Impact factor: 7.620
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.